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“Science! true daughter of Old Time thou art! 
Who alterest all things with thy peering eyes. 
Why preyest thou thus upon the poet's heart, 
Vulture, whose wings are dull realities? 
How should he love thee? or how deem thee wise? 
Who wouldst not leave him in his wandering 
To seek for treasure in the jewelled skies” 
 
 
 
 
 
“Sonnet: To Science” 
 
Edgar Allan Poe 
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Abstract 
 
A fructose rich diet has been known to have nefarious effects on both mice and 
humans. However, the effects of this diet upon the intestine and surrounding tissues are 
still unclear. The intestine and the liver are the only organs that absorb fructose directly 
into metabolic processes, and are tightly connected via bile duct and hepatic portal vein, 
which means they both influence each other in the process, forming the intestine-liver 
axis. This connection makes this axis susceptible to inflammatory and metabolic changes. 
The present work intends to show how a fructose rich diet can affect the intestine’s 
permeability, and how a change in permeability can affect the expression of certain 
proteins in liver in mice. 
 In this study we compared a fructose rich diet versus normal chow over the course 
of three months. Intestinal permeability was evaluated by gavaging a fluorescent probe 
(FITC-dextran) into fasting mice. The amount of probe present in blood was correlated 
with permeability. Protein expression levels in liver were quantified by Western blot, in 
which peroxisome proliferator associated receptor alpha and beta, tumor necrosis factor 
alpha and glucose transporter 2 were measured. 
Intestinal permeability in high fructose fed mice was consistently and significantly 
higher than in the control mice in all time points. The data also suggests that there is an 
adaption of the intestine to the diets, as both control and experimental group have an 
increase in permeability until week 6, but both had a significant reduction in this value at 
week 12, which would mean that the intestine recovered some of its integrity. Western 
blot in the liver revealed an increase in cytokine expression (tumor necrosis factor alpha) 
as well as fructose associated transporters (glucose transporter 2). Expression of anti-
inflammatory nuclear receptor peroxisome proliferator associated receptor alpha was 
decreased while its beta form was unchanged. 
 In this work it was possible to conclude that a fructose rich diet damages the 
intestine, which leads to a higher intestinal leakage than a regular diet would. Such 
increased leakage releases toxins and metabolites into the blood stream, directly affecting 
the liver, resulting in an increase in inflammation and fructose transport.  
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Resumo 
 
A dieta rica em fructose é conhecida por causar efeito nefastos em ratos e em humanos. 
Contudo, os efeitos desta dieta no intestino e nos orgãos circundantes são ainda pouco 
claros. O intestino e o fígado são os únicos orgãos que absorvem fructose directamente 
para os seus processos metabólicos, e estão intrisecamente ligados entre eles pela vesícula 
biliar e pela veia portal hepática, o que significa que ambos se influenciam um ao outro 
no processo, formando assim o eixo intestino-fígado. Esta conecção torna este eixo 
susceptível a mudanças inflamatórias e metabólicas. O presente trabalho predispõe-se a 
mostrar de que forma é q uma dieta rica em fructose pode afectar a permeabilidade 
intestinal, e como é que uma mudança de permeabilidade pode afectar a expressão de 
certas proteínas nos fígado de ratinhos. 
 Neste estudo comparou-se uma dieta rica em fructose contra uma dieta normal no 
decorrer de três meses. A permeabilidade intestinal foi avaliada através da gavagem de 
uma sonda fluorescente (FITC-dextran) em ratinhos em jejum. A quantidade de sonda 
presente no sangue foi correlacionada com permeabilidade. Os níveis de expressão de 
proteína foram quantificados por Western Blot, nos quais foram medidos os níveis dos 
receptores associados a proliferação de peroxissoma alfa e beta, factor de necrose tumoral 
alfa e o transportador de glucose 2. 
 A permeabilidade intestinal dos ratinhos alimentados a dieta de fructose foi 
consistemente e significativamente mais alta que a do grupo controlo em todos os pontos 
temporais. Estes dados sugerem que há adaptação do intestino às dietas, visto que tanto o 
grupo de controlo como o grupo experimental tiveram a sua permeabilidade aumentada 
até à semana 6, mas ambos tiveram uma redução significante desse valor na semana 12, 
o que significa que o intestino recuperou alguma da sua integridade. Western blots no 
fígado revelaram que houve um aumento na expressão de citoquinas (factor de necrose 
tumoral alfa), tal como no transportador associado a fructose (transportador de glucose 
2). A expressão do receptor nuclear anti-inflamatório associados a proliferação de 
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peroxissoma alfa foi reduzida, enquanto que os valores da sua forma beta se mantiveram 
inalteráveis. 
Neste trabalho foi possível concluir que uma dieta rica em fructose danifica o 
intestino, o que vai levar a mais “vazamento” intestinal do que uma dieta normal. Tal 
aumento de permeabilidade vai corresponder a um aumento de toxinas e metabolitos na 
corrente sanguínea, afectando directamente o fígado, resultando num aumento em 
inflamação e em transporte de fructose. 
 
Palavras chave: dieta rica em fructose; permeabilidade intestinal; receptores nucleares 
hepáticos;
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1. Introduction 
 
1.1 Fructose in diet & Consumption 
 
 Fructose is a sugar that is naturally present in fruit and is also widely used in 
preserved food and sweetened beverages.  Due to the increased availability and use of 
high-fructose corn syrup, fructose consumption in Western countries is rising at an 
alarming rate. A diet rich in fructose has been shown to provoke adverse alterations in 
carbohydrate and lipid metabolism in both animal models and humans. To date, the 
adverse effects of high fructose consumption have been explained in terms of its direct 
effects on hepatic metabolism.  However, high fructose consumption may also indirectly 
influence hepatic metabolism through hitherto undefined effects on the intestinal 
microflora. 
High fructose corn syrup is a cornstarch derived product.  Glucose results from 
hydrolysis of starch and after isomerization of glucose, it is possible to obtain fructose. 
Before this syrup is complete it goes through chromatographic fructose enrichment, 
which will make this 90 % of this syrup rich in fructose1,2. 
Nowadays, fructose is present in many types of food as a sweetener and its usage 
contributes to higher sugar diets.  In the United States of America from 1978 to 2003 3 
the consumption of fructose increased 17%, replacing sucrose as one of the main 
sweeteners (sucrose availability in food supply decreased about 32%). It is usually added 
in non-alcoholic beverages, which are the main source of fructose intake, particularly in 
children and young adults. In weight terms, this translates into an amount of 69 kg of 
fructose consumed per capita per year4–6 . Fructose and sugar sweetened beverages have 
a high impact on health , and can lead to hypertriglyceridemia and other metabolic 
syndromes7–9. 
 
1.2. NAFLD:  an important outcome of high fructose consumption 
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 Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease which is 
characterized by a diagnosis of excessive triglyceride accumulation in the liver as 
measured by liver biopsy or magnetic resonance spectroscopy 10–12.  The incidence of 
NAFLD has risen in line with a steep rise in fructose consumption, hence excessive 
dietary fructose intake is highly implicated as a risk factor. NAFLD is also associated 
with both obesity and insulin resistance13–15 and is considered to be an early milestone 
toward development of Type 2 diabetes.   
The overall incidence of NAFLD in obese and diabetic individuals is between 60 
and 80 %, rising to near 100% in morbidly obese patients16. Both NAFLD and obesity 
are associated with systemic and hepatic insulin resistance17,18.  Peripheral tissues 
contribute to hepatic lipid overload and insulin resistance by increased release of non-
esterified fatty acids and pro-inflammatory factors into the blood stream 19,20,21 . NAFLD 
can also act as a gateway to more severe liver disease, and can eventually progress to 
nonalcoholic steatohepatitis (NASH), which is a condition in which there is lobular 
inflammation as well as elevated fat deposits of the liver22, which can be diagnosed via 
biopsy23.  NASH can further progress into cirrhosis, which is characterized by extensive 
fibrosis of the liver and overall loss of hepatic function24. 
While NAFLD disease presents similar symptoms to the initial stages of alcoholic 
fatty liver disease 25,26, it is considered to be independent of alcohol intake27.  However, 
despite an absence of ethanol intake, it is possible that the liver could be exposed to 
intestinal ethanol generation via bacterial fermentation (see later section).  The extent to 
which this could contribute to NAFLD pathology is not known.  
Excessive fructose intake can have negative effects on the liver through direct and indirect 
ways27.  Direct mechanisms include the generation of toxic intermediary metabolites, and 
a temporary decrease in adenosine-triphosphate (ATP) levels by fructokinase and 
triokinase activites28.  As will be subsequently discussed, indirect mechanisms include an 
increased inflammatory response that may originate from alterations in intestinal 
microflora and their interactions with enterocytes.  Also, high fructose intake (coupled 
with intestinal malabsorption) may result in altered production of fermentative 
metabolites by intestinal bacteria, including possibly ethanol.  Metabolite and 
inflammatory factors act synergistically to promote hepatic lipid accumulation and insulin 
resistance. 
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1.3 Fructose uptake & metabolism  
Fructose is initially absorbed passively into the enterocytes (eukaryotic cells that share 
the intestine with bacteria and fungi). The enterocytes are the intestine’s epithelial cells 
whose function is to absorb nutrients and to send them to the bloodstream, through the 
intestine-blood barrier29. Fructose is carried to the blood stream via glucose/fructose 
facilitated transporter 5 (GLUT5) which is a low affinity high capacity bi-directional 
fructose transporter, and GLUT2, another hexose transporter, also present in the 
membrane of enterocytes30,31.  Under-expression of intestinal GLUT5 is associated with 
malabsorption of fructose30. Fructose can also be metabolized in the intestine prior to 
intestinal absorption and may 1) result in increased levels of potentially harmful bacterial 
fermentation products such as ethanol and 2), alter bacterial numbers and species 
distribution that constitute the intestinal microflora. Since the intestine is one of the 
primary nutrient absorption source 32, the type of nutrients that are absorbed affect the 
whole human body 33–38.  
 
The hepatic portal vein drains the intestinal bed and directly delivers the absorbed 
nutrients to the liver.  Absorbed fructose is taken up by the liver via GLUT5 transporters.  
Following absorption, fructose is phosphorylated by fructokinase to make fructose-1-
phosphate.  Expression of this enzyme is up-regulated by fructose, so an increase in 
fructose uptake results in increased fructokinase activity. Fructose-1-phosphate is 
metabolized by aldolase to make dihydroxyacetone phosphate and glyceraldehyde.  This 
latter metabolite can be phosphorylated via triokinase to form glyceraldehyde 3-
phosphate and enter glycogenesis. Both glyceraldehyde and dihidroxyacetone phosphate 
will form  of these will form a pool of triose phosphate that can be converted to pyruvate, 
which in turn is be able to form acetyl-CoA (which can be further metabolized in the 
Krebs cycle) and citrate inside the mitochondria . 
Unlike glucose metabolism, the uptake of fructose in the liver bypasses two of the 
main rate-determinant enzymes in hepatic glycolysis, glucokinase and 
phosphofructokinase. Glucokinase is an insulin sensitive high flux controller for 
gluconeogenesis in the liver39, that can also mediate the coupling of glycolysis to 
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mitochondria at low glucose levels 40. This kinase converts glucose to glucose-6-
phosphate. Its activity is not affected by the presence of glucose-6-phosphate and it has 
low affinity for glucose.41 Phosphofructokinase is an unidirectional enzyme which 
converts fructose-6-phosphate, that comes from normal glycolytic metabolism, into 
fructose-1, 6-biphosphate. This reaction is crucial in glycolysis, and can be inhibited by 
ATP and citrate42 . Phosphofructokinase has also been reported to interact indirectly with 
glucokinase, as fructose-6-phosphate can repress this enzyme, through interaction with 
glucokinase receptor protein43. Another important factor that distinguishes fructose 
metabolism in the liver from the glucose one is the different insulin dependence, since 
insulin is the main inducer of phosphofructokinase and glucokinase 36,44,45. 
The uptake of fructose by the liver can also lead to increased hepatic 
gluconeogenic and lipogenic fluxes, which can disrupt the liver’s function in regulating 
blood glucose and triglyceride levels. Gluconeogenesis is sustained by the inflow of triose 
phosphate products of fructose catabolism46.Thus, following a bolus of fructose, plasma 
glucose levels show a rapid increase, reflecting an increase in endogenous glucose 
production that is fuelled by gluconeogenesis from fructose36,47  
Fructose can also contribute to the hepatic glycogenesis through an indirect 
pathway, which initially involves phosphorylation of fructose into fructose-1-phosphate. 
Fructose-1-phosphate will be cleaved into glyceraldehyde and dihydroxyacetone 
phosphate. After glyceraldehyde is phosphorylated to glyceraldehyde-3-phosphate, it will 
be joined with dihidroxyacetone to make fructose-1,6-biphosphate. This reaction will be 
followed by formation of glucose-6-phosphate and end in the formation of glycogen via 
glucose-1-phosphate and UDP-glucose46 . 
The stimulation of hepatic de-novo lipogenesis is another important change that 
is attributed to high fructose consumption. Metabolism of its triose phosphate 
intermediates to acetyl-CoA is postulated to increase the supply of acetyl-CoA precursors 
for the de novo lipogenesis pathway.  In addition to supplying the carbons for de novo 
lipogenesis, alterations in hepatic sugar phosphate intermediates and other metabolites 
resulting from fructose metabolism may also upregulate the transcription of novo 
lipogenesis enzymes36,48.   Increased lipogenic activity is coupled to increased export of 
very low density lipoproteins (VLDL) resulting in a rise of plasma VLDL levels49–51.  
VLDL are TAG-rich lipoproteins that are highly atherogenic and are well known risk 
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factors for cardiovascular disease.  Increased VLDL flux is also associated with the 
accumulation of triglycerides in tissues other than adipocytes, such as skeletal muscle and 
pancreas.  These so-called ectopic lipid pools are characteristic of dyslipidemia and are 
tightly associated with the development of insulin resistance in the afflicted tissue.  
Based on its effects on hepatic intermediary metabolism, an excess of fructose is 
expected to increase hepatic triglyceride and VLDL production. Given this, it is plausible 
to hypothesize that high fructose consumption induces insulin resistance in part via 
alterations in hepatic and systemic lipid metabolism52,31,36,47,53,54. 
 
 
 
Figure 1: Overview of the reactions that fructose can partake in the cell. Adapted from 
Tran et al, 2009 55. 
 
Insulin resistance may be conferred by hereditary and by environmental factors.  
Environmental mechanisms include epigenetic modifications of gene expression 56 and 
over-nutrition 34,35,57,58.  Altered nutrient intake may also induce changes in the species 
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distribution and metabolic activity of intestinal microbiota which may in turn result in 
exposure of the liver to agents that promote the development of insulin resistance 32,38,59–
62.  Since the focus of this thesis is to study the promotion of fructose-induced hepatic 
insulin resistance via mechanisms likely related to intestinal microbial activity, intestinal 
microflora and their interactions with intestinal function will be discussed in more detail. 
The intestine can be considered as a system composed of two main metabolic 
parts: enterocytes and microbial flora. Each has a specific type of metabolism, and both 
have access to a wide range of nutrients. The intestine’s commensal flora and the 
enterocytes are separated by a mucus layer that protects the enterocytes from bacterial 
endotoxin, which among other things, are highly pro-inflammatory.  The interplay 
between flora and enterocytes can dictate our susceptibility to diet-induced complications 
such as insulin resistance (Figure 2).   
 Enterocytes are polarized epithelial cells connected between each other by tight 
junction, whose main function is to transfer nutrients including fructose30.as well as 
fasting inducing factors into the blood stream.. Absorption is mediated by two different 
mechanisms: passive diffusion and protein-mediated transport63. 
Since the intestine is the gateway for nutrient absorption into the bloodstream, it 
is hypothesized that intestinal microbial metabolic activity can have effects on 
metabolism of the host tissues and organs.  For example, short-chain fatty acids such as 
acetate and butyrate that are generated by microbial fermentation contribute to muscle 
energy metabolism; acetate can also potentially sustain hepatic lipogenesis, while other 
products (like L-α -Lysophosphatidylinositol64) may activate G coupled protein receptors 
(GPR) that are connected with obesity and insulin resistance 60,64,65.  
An output “burst” of fatty acids from the intestine can also lead to the production 
of cytokines like fasting induced adipose factors (FIAF), which are involved with energy 
homeostasis66,67  through the regulation of fat storage. The intestine also receives lipid 
products from whole body catabolism of sterols via the bile circulation.  In addition to 
serving as emulsifying agents for solubilizing dietary triglycerides, these products can 
also be metabolized by intestinal bacteria to form conjugated bile acids, which can be 
recirculated into the host. 
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Bile is synthetized in hepatocytes and is stored in the bile ducts before being 
excreted into the gallbladder, where it stays until the gallbladder contracts after meals to 
pump bile acids into the intestine through the common ducts to mix with the food present 
there. Bile is a micellar aqueous solution of salts, bilirubin, bile acids and proteins, 
phospholipids and cholesterol. Bile acid salts are reabsorbed in the small distal bowel, 
directly into the portal vein to be taken up by the liver68. It is important to note that bile 
can help break down cholesterol into cholic and chenodeoxycholic acid, which can be 
used to produce more bile, but its main function is to act as physiological detergent for 
transport and absorption of nutrients69. 
Excessive fructose may lead to higher lipid output from the liver to the 
gallbladder, which in turn will emulsify these lipids (with bile) and increase the efficiency 
of intestinal lipid absorption 36,44,70  
 
1.5 Intestinal microflora 
 
 
Figure 2 Schematic representation of how the muscle, liver and adipocytes are dependent 
on the intestinal metabolic reactions. SCFA stands for short chain fatty acids, and FIAF 
stands for fasting induced adipose factors Adapted from Cani et al, 2011, 49. 
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Intestinal microorganisms account for nearly 90 % of the total body cell number 
61 .The gastrointestinal organisms have different distributions in this system, as each 
organ has a different micro environment and different metabolic function. The stomach 
has the least bacteria, with 103 colony forming units (CFU) per gram of gastric juice. The 
small (or upper) intestine (duodenum and jejunum) also have a low count of bacteria, with 
about 102-104 CFU per gram of content, while increasing greatly in number as you reach 
the end of the gastrointestinal system, with ileum accounting for 1010 CFU per gram and  
the colon harbouring around 1010-1012 CFU per gram71 .If there is an increase in the 
number of bacteria in the small intestine it can cause small intestine bacterial overgrowth, 
which is an unhealthy condition associated with malabsorption72. This condition can 
happen in cases where fructose cannot be absorbed correctly in the small intestine so 
colonic bacteria have to metabolize more fructose, since metabolization of fructose by 
bacteria will make hydrogen, carbon dioxide and short chain fatty acids 73,74. These 
bacterial products will cause enterocyte luminal distention and contribute to the nausea, 
abdominal discomfort and gas formation that are felt in small intestinal bacterial 
overgrowth. 
Their principal sources of energy include simple and complex carbohydrates.  For 
clearance of simple carbohydrates such as fructose and glucose, intestinal absorption 
competes with microbial metabolism. Impaired absorption of carbohydrate is therefore 
expected to increase its availability to intestinal bacteria.  In the case of fructose, intestinal 
GLUT5 deficiency can limit its absorption and potentially provide intestinal bacteria with 
fructose for fermentation.  This may explain symptoms of discomfort and excessive gas 
production in GLUT5-deficient individuals 30. Complex carbohydrates are not digested 
by endogenous intestinal enzymes, nor are they transported into the bloodstream. 
Complex carbohydrates are fermented by colonic bacteria to make SCFA, of 
which butyric acid, propionic acid, and acetic acid are the main products75. Acetic acid 
can cross the intestinal-blood barrier and reach the portal vein, where it can be absorbed 
into the liver to be used in the form of acetyl-CoA76. This and other SCFA derived 
products can then be used in the liver as precursors for Krebs cycle oxidation, 
lipogenesis77, and gluconeogenesis 78. 
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For simple carbohydrates, the Crabtree79 effect happens whenever bacteria80,81, 
yeast82–84 and even eukaryotic cells85,86 have access to high levels of sugar , and 
metabolize them to ethanol. 
 
 
 
Figure 3 Schematic representation of the Crabtree effect in microorganisms. "1" 
represents glycolysis pathway. "2" represents Entner Doudoroff pathway. "3" represents 
methyl glyoxal bypass/glyoxilate system. Adapted from Pronk et al , 1996,135 
 
In addition to glycolysis, bacterial also possess the Entner Doudoroff and glyoxal 
bypass pathways (Figure 3). The Entner Doudoroff87,88 pathway is a prokaryote exclusive 
pathway that acts as an alternative way (for some bacteria) to convert glucose to pyruvate. 
This pathway is usually associated with bacteria that lack some of the glycolytic enzymes, 
and can allow bacteria such as E. coli to use fructose as sole carbon source89. The methyl 
glyoxal pathway is also a glycolysis bypass90, which is mostly found in prokaryotes. 
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 The intestine is mostly filled with gram negative bacteria, its main strains are 
specifically Bacterioidetes and Firmicutes (this type has gram positive and negative 
strains). These two strains have an impact on how the gastrointestinal system behaves 
because they are envolved with intestinal mucosa immunity development and help the 
intestine in controlling bacteria by stimulation of the mucosa to produce 
immunoglobins91. It has also been reported that gram-negative bacteria are the main 
source of endotoxin from the intestine92. Due to the great number of gram negative 
bacteria in this system and due to the tight control of the balance between inflammation 
and symbiosis, any alteration in bacterial or enterocyte metabolism will have 
repercussions on the intestine itself. 
 
1.5 Intestinal permeability 
 
Intestinal permeability is now considered as an important factor in the 
development of hepatic insulin resistance. The quantity and type of leaked microbiota 
(species, metabolites and toxins) may trigger inflammatory and other processes in both 
enterocytes and adjacent tissues and organs, such as visceral fat and liver.. There have 
already been some studies on the effects of high-fat diet on inflammation of the intestine 
and surrounding tissues in mice 33–35,37,38,57,93.  They indicate that high fat feeding per se 
does not completely explain the observed inflammation, However it is implied that 
altering the intestinal permeability conjugated with endotoxin leakage should help justify 
the low grade inflammation set on metabolic diseases like NAFLD26,94–96 and insulin 
resistance 32,62,97–102.  
Non-invasive intestinal permeability assays have been used since the 1970’s and 
103,104,105.  All these tests use the same principle: oral administration of a large-molecular 
weight substance that is not metabolized in the intestine and is not transported by the 
normal enterocyte nutrient transporters, followed by its detection in blood or urine.  The 
substance may be tagged with a fluorescent group to aid its detection by fluorescence 
emission spectroscopy, for example FITC-dextran59,105 Alternatively, the substance may 
be identified and quantified by HPLC or NMR spectroscopy106.  In any case, the higher 
the levels of the substance measured in blood or urine, the greater the degree of intestinal 
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permeability.  While these methods do not provide absolute values of intestinal 
permeability, their non-invasive nature means that they can be used to assess relative 
changes in permeability following dietary or other interventions. 
Endotoxin leakage and generation  of an inflammatory response in surrounding 
sites known to be influenced by diet 65,94,107.  One possible explanation is that a particular 
diet modifies the species and distribution of bacteria that in turn results in an increased 
permeability to endotoxin leakage 59,62,108. 
 
 
Figure 4 Overview of the diet´s effect on the intestine and it´s inflammatory properties. 
Adapted from Burcelin et al 11 
 
Figure 4 illustrates some proposed mechanisms that link diet-induced changes in 
intestinal bacteria to systemic inflammation.  Increased intestinal permeability can allow 
translocation of endotoxin or even entire bacteria into surrounding tissues including liver, 
mesenteric fat and adipocytes thereby contributing to inflammation and metabolic 
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deregulation of these tissues94,95,107,109–117.  While the extent of bacterial or endotoxin 
translocation and resulting systemic response are far below the catastrophic effects 
associated with sepsis or intestinal perforation, it is becoming increasingly clear that the 
sub-acute but chronic inflammation response is a key factor for promoting hepatic insulin 
resistance. 
  
1.6 Endotoxin and inflammation mechanisms 
 
The main endotoxin produced by the intestine´s microbiota is LPS. LPS is a 
powerful endotoxin produced by Escherichia coli and other gram negative bacteria  118,119. 
LPS is considered to be the main endotoxin excreted by the intestine´s flora and is known 
to induce Toll like receptor 4 (TLR4) 111,120–123 stimulates inflammation in various tissues 
such as adipocytes 96,114,115,124,125, kidney 111, pancreas98,126–129 and is nowadays 
considered to contribute to development of insulin resistance 32–34,38,56,57,59,62,98–102,130,131, 
NAFLD27,126,132 and cirrhosis26,107,111. The chronically elevated levels of circulating 
endotoxin constitutes a low-grade endotoxemia119,126,133,134, and has been associated with 
over nutrition.  
Toll Like Receptors (TLR) are pathogenic “sensors” found in vertebrates that 
modulate inflammatory response62, and control the host´s innate response, which are 
usually present in macrophages and dendritic cells. TLR 4 is a specific receptor for LPS  
62,121, (and its co receptor CD14) (figure 5), that triggers release of cytokines, such as 
TNFα, IL-6, SOCS-3 and SOCS-6. TLR4 is expressed in adipocytes, hepatocytes62 and 
Kupfer cells135  
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Figure 5 Overview of the TLR4 activation pathway by LPS recognition. Adopted from 
Jerala et al 156 . 
After its release from intestinal bacteria, LPS exists as multimolecular aggregates.  
Lipid binding proteins (LBP’s) “dismantle” these aggregates and transfer individual  LPS 
molecules to CD14 136 and MD-2 (which binds exactly one LPS molecule per MD-2). It 
is important to note that LBP’s are also involved with chylomicron metabolism, as both 
LPS and chylomicron have lipid A in their structure. There is also the possibility of a 
trimeric CD14:LPS:MD-2 complex as the final product of this pathway118. Activation of 
TLR4 is mediated by the CD14:LPS and MD-2:LPS complexes which leads to the 
inflammatory response. 
The capacity of LPS to induce an immune response response is determined in part 
by the number of Lipid A “units” it contains. The higher the lipid A in LPS, the higher 
affinity it has to bind LBP 118,137 (Figure 5)  Theoretically, if there is excess lipid available, 
part of it may be converted into lipid A, which can be incorporated in LPS “assembly” 
thereby modifying its core and augmenting its inflammatory capacity.  Toll like receptor 
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activation is also associated with recruitment of other inflammatory factors, mostly 
interleukins and tumor necrosis factor alpha TNF-α) 138. The latter stands out since it is 
not dependent on macrophage activation to be produced (although macrophage activation 
also contribute). TNF-α, is associated with inflammation and is known to be involved 
with fructose induced metabolic syndromes 139.  However, since TNF-α secretion is 
triggered by a variety of factors, it is not known to what extent bacterial or endotoxin 
translocation contributes to elevated TNF-α levels in diet-induced insulin resistance.  
 
1.3 Nuclear Receptors: a link between inflammatory factors and metabolism 
 
 Nuclear receptors are a class of molecules that act directly on the cell’s nucleus 
and are tightly connected to metabolism. There are two main classes of these receptors: 
liver X receptors and peroxisome proliferator activated receptors.  Liver X receptors 
(LXR) are nuclear receptors associated with regulation of cholesterol and lipid 
metabolism140–146, They form heterodimers with Retinoic X receptors, and are also 
involved with peroxisome proliferator associated receptors147,148. However these 
receptors have a role that goes beyond metabolic regulation, as they are also implied in 
inflammatory response. The various isoforms of LXR 149, are known to be present in vital 
organs and cell types, specifically the liver, intestine, kidneys, adrenal glands, adipose 
tissue and macrophages 150. This also contributes to the idea that nuclear receptors are 
important “players” in lipid metabolism, as all of the above deal with high access to lipids. 
   LXR activation151 can happen by cholesterol and will lead to its efflux, until 
homeostasis is recovered. However in diseases like atherosclerosis this activation can be 
excessive in macrophages and lead to the downregulation of membrane cholesterol 
transporters and eventually lead to unhealthy lipid accumulation, this is what causes the 
formation of foam cells 140,152. 
LXR’s can a be activated via general inflammatory receptors, specifically 
interleukin receptors, toll like receptors and tumor necrosis factor receptor, the latter two 
are also activated by lipids 112,114,139,153,154. LXR also doubles as an anti-inflammatory 
mediator when activated by these receptors 140,141,144–146,151,155. This just shows that LXR 
as a nuclear receptor can adapt according to the activation it received, which ends up 
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being a double edged knife, because over stimulation can have different outcomes156. This 
can be seen in NAFLD, where it is known that LXR is expressed in abnormal levels 157. 
 
1.3.1 Peroxisome Proliferator Activated Receptors 
 
 Peroxisome proliferator activated receptors (PPAR’s) are orphan nuclear 
receptors, which are activated by free fatty acids142,158, and much like LXR’s they also 
deal with metabolism and inflammation. These receptors act as transcription factors that 
can induce changes in the expression of other genes when activated. It is known that there 
are different types of PPAR’s and that each one has a different function, besides being 
present in a different site, in table 1 we can see more details on the matter. 
Type of 
PPAR 
Site of expression Function References 
PPAR 
alpha 
Liver, kidney, heart, 
endothelial cells, skeletal 
muscle, macrophage 
Mediator of lipoprotein 
metabolism; anti-
inflammatory effector, 
control lipid homeostasis in 
macrophages 
149,159–161 
PPAR 
beta/delta 
Ubiquitously expressed Regulates inflammatory 
response, lipid metabolism 
and cell proliferation, can 
modulate insulin 
sensitivity. 
147,162–167 
PPAR 
gamma 
Adipose tissue, immune 
cells, dendritic cells, colon, 
spleen, smooth muscle, 
retina 
Adipose differentiation, 
lipid metabolism 
homeostasis, modulator of 
insulin action, in charge of 
anti-inflammatory action 
142,159,168–172 
 Table 1 Depiction of the PPAR types, location and function 
 Figure 6 shows a quick summary of how PPAR’s work in the cell, when 
inflammatory bursts like TLR are laid out, but these are not the only events that trigger 
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the PPAR’s. Lipid metabolism derivatives are one of the main activators of PPAR and 
each type of PPAR can be activated or repressed depending on what molecule binds to it. 
Leukotriene B4 and hydroxyeicosatetraenoic acid are known to successfully activate 
PPAR α, both these molecules come from arachidonic or linoleic acids after going 
through the cyclooxygenase and lipoxygenase pathways173–176 and acyl-CoA’s, which 
basically means that after going under oxidative metabolism these fatty acids may interact 
with PPAR, but most unsaturated fatty acids should be able to deal with at least one type 
of PPAR. PPARβ can be activated by 15-deoxy-prostaglandin and 15-HETE, 
prostacyclin, while PPAR γ is only known to be activated by 9-HODE 
(hydroxyoctadecadienoic acid) and 13-HODE. Co factor recruitment has also been 
described with the most studied one being rosiglitazone (an insulin sensitizer that also 
increases adiponectin171), that can act as an agonist for PPAR170,177,178. 
 
Figure 6 General representation of the PPAR pathways 
 
 Just like the liver X receptors, PPAR’s also form heteromdimers with RXR, this 
will lead to some competion for binding sites and it has been reported that they can even 
downregulate each others expression147. After the PPAR has had stimulation it will 
proceed to bind with the peroxissome proliferator response element (PPRE) sequence (in 
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the nuclei) and depending on the PPAR form it will act on different regions and help 
express diferent proteins179 (figure 7), PPAR β can even inhibit expression of the target 
genes for PPARα and PPARγ180,181.   
PPAR α is the most studied of this subfamily of nuclear receptors, and is known 
to promote expression of many proteins essencial for metabolic pathways, this can be 
particularly important in the liver. There are too many proteins regulated by this PPAR 
to mention here, but I will mention some of the most important. Regarding fatty acid 
metabolism , Acyl-CoA oxidase, one of the enymes that starts the β-oxidation process in 
acyl-CoA chains, ketogenic enzymes, fatty acid uptake genes (Abcd2 and Abcd3) , are 
related to PPAR α. Some mitochondrial uncoupling proteins and dehydrogenases are also 
expressed via PPAR α activation, as well as some lipogenic and some “major” fatty acid 
binding proteins like fatty acid binding protein 1 through 5. PPAR α can also help control 
lipoprotein pathways and lower fasting tryglicerydes and raise plasma high density lipids. 
Glucose and glycerol metabolism is also mediated by this receptor, as the genes for 
phosphoenolpyruvate kinase 1, pyruvate carboxylase and lactate dehydrogenase A are 
targets for PPAR α. These targets are just a small fraction of what PPAR α can interact 
with, it is also important to consider the regulation of bile acid production and amino acid 
metabolism are also a part of its many targets. 
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 Figure 7 General representation of PPAR activation 84  
Just as LXR’s, PPAR α has a strong connection with inflammatory targets, 
although its activity is far more anti-inflammatory than the remaining PPAR’s. Just like 
the metabolical aspect of PPAR α only a part of the inflammatory genes will be 
highlighted, as this receptor also acts as an important regulation factor for many of these 
genes. C-jun and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) 
both transcription factors associated with inflammatory response to cellular stress 70,162,182 
are inhibited by PPAR α. Fibronogen, C-protein, interleukin and TLR expression is also 
repressed by PPAR α activation183–185. As we can see PPAR is one of the best candidates 
for studying when considering diet induced liver damage, since it can stimulate fatty acid 
oxidation and downregulate hepatic inflammation. 
 PPAR β and γ action mechanisms are quite unclear at the moment, however there 
are some correlations that have already been made. PPAR β can act as a toxicity handler, 
and is known to protect the liver by regulating CD14, NF-kβ, calcium binding proteins, 
cyclin D1 and kinase signalling 162,186–189. PPAR γ is even less studied, as only indirect 
evidence for its function has been provided yet, and little is known of its target genes. 
However, its connection with adipogenesis has been proved168, as well as a relationship 
between this receptor and insulin sensitivity and beta-oxidation172,188.  Thus, LXR’s, 
PPAR’s and cytokines work hand in hand during alterations in metabolic and 
inflammatory states.  More generally, hepatic nuclear receptor expression feels the 
repercussions of altered intestinal microbiota.  
  
1.8 Objectives / Scope of this work 
 
 As seen in previous sections there is justification in considering the effects of a 
fructose rich diet on the intestinal-liver axis as an important contributor to the 
development of fatty liver disease and insulin resistance.  To date, indirect intestine-
mediated mechanisms of hepatic injury from high fructose feeding have been much less 
studied in comparison to those attributed to direct modifications of hepatic intermediary 
metabolism.  Therefore this study aims test the primary hypothesis that high-fructose 
feeding results in and increased intestinal permeability and the secondary hypothesis 
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that increased intestinal permeability is associated with a pro-inflammatory expression 
of hepatic nuclear receptors and cytokines.  
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2. Methods 
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2. Methods 
 
2.1 Mice keeping and diet 
 
In this study the experimental group mice were fed with 60 % fructose (the only 
sugar intake in this diet) and 40% of other nutrients for 12 weeks. This diet has a value of 
3,6 kcal for gram, and for each 100 calories we have 20,2 calories of protein, 66,8 calories 
of carbohydrates and 12,9 calories of fat. After the 12 weeks mice were sacrificed, that 
time frame was used to evaluate metabolic and physiological changes, as it is common to 
have mice dieting for this long in diet based studies26,93,96,105. The control group was 
composed of mice fed with normal chow, which contains the following in g per kg of 
chow: casein, 200 g/kg; L-cysteine, 3 g/kg; corn starch, 397,486 g/kg; maltodextrin, 132 
g/kg; sucrose, 100 g/kg; soybean, 70 g/kg; cellulose, 50 g/kg; mineral mix, 35 g/kg; 
vitamin mix, 10g/kg; choline bitartarate, 2,5 g/kg; tert-butylhydroquinone (antioxidant), 
0,014 g/kg. The mix in normal chow corresponds to 3,8 kcal/g , and for 100 calories it 
has 18,8 calories from protein, 63,9 calories from carbohydrates and 17,2 calories from 
fat, which means that even though this diet is different from the high fructose diet, both 
have nearly the same amount of calories from fat, protein and carbohydrates. The diet in 
the control group is the standard rodent “baseline” for metabolic and nutritional studies. 
 
2.2 Blood collection and Intestinal Permeability 
 
The intestinal permeability assay used in this work, is based in the method 
described by Cani in 2009 104. It consists on using a fluorophore molecule, FITC-dextran, 
which has a high molecular weight (4.4 kDa) to acess whether or not there has been 
intestinal damage. The FITC-dextran was gavaged to mice, and one hour later blood was 
collected from the tip of the tail, to be treated with PBS buffer and read on a fluorometer. 
The fundament behind this assay is that FITC-dextran is not able to cross the intestinal 
barrier and leak out into the blood current in a healthy situation, at least not in a 
quantifiable way 104. In a situation of intestinal leakage the probe will be able to get to the 
portal vein, and we are able to establish a relationship between fluorescence and leakage, 
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since higher concentrations of probe in the blood stream can be associated with higher 
leakage, which in turn correlate with a damaged intestinal mucosa. 
The mice were gavaged with 6,5 µg of Fluorescein isothiocyanate-Dextran (FITC-
Dextran), average molecular mass 4.4 kDa, after fasting for at least 4 hours. The mice 
rested for an hour before being subjected to infrared light (to cause vasodilation). With 
the aid of a surgical blade, the mice had their tail tip cut and 100 uL of blood was collected 
from it.  The blood samples were centrifuged at 13,000 relative centrifuge force (RCF) 
for 10 minutes. Afterwards the supernatant plasma was recovered (50 µL) and added to 
equal volume of phosphate buffered saline (PBS) buffer. 
These samples were transferred to a 96 well plate with clear bottom and read in 
the fluorometer. The excitation and emission wavelength were set at 425 nm and 535 nm 
respectively, for this is the setting used for fluorescence assays with FITC molecules 
59,122,190–192. The presence of FITC-dextran was quantified in each sample after obtaining 
a concentration curve of this molecule in blood (1:2 dilution),  prepared according to 
literature59. Calculation of intestinal permeability was done by calculating the 
concentration of probe in the mice’s blood, quantifying the probe for whole mice blood 
and then a comparison with the gavaged quantity. 
 
2.3 Tissue Collection 
  
 After three months of dieting the mice were sacrificed for organ collection. The 
mice were sacrificed at the start of the light period and were therefore in the early 
postabsorptive phase.  They were anesthetized with haloethanol and killed by cardiac 
puncture.  Liver was collected in aseptic conditions to avoid bacteria leakage, fat was 
scraped from the samples collected to ensure the least metabolite and protein 
contamination. The livers collected were kept in -80º C. 
 
2.4 Western Blots 
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 Western blot was used to evaluate the quantity and to identify proteins present in 
samples193–195, since it is a simple technique for obtaining intracellular protein expression 
levels, while quantifying them via fluorescence. 
 
2.4.1 Cell lysate preparation 
 
5 grams of liver for each sample were weighed and homogeneized in 400 uL of 
cold RIPA (radio immuno precipitation assay) Buffer. RIPA was prepared with 20 mM 
Tris HCl pH 7.4, 25 mM NaCl, 1% NP-40 (Nonidet P-40), 5 mM EDTA, 10 mM Sodium 
diphosphate (Na4P2O7), 10 mM Sodium Fluoride (NaF), 2 mM Sodium Vanadate 
Na3VO4, 10 μg ml-1 Aprotinin from bovine lung, 1 mM Benzamidine and 1 mM 
Phenylmethylsulfonyl fluoride (PMSF), (Sigma-Aldrich, St. Louise, MO, USA)) .  
Cell lysates were homogeneized 3 times at 13500 rpm on a ULTRA-TURRAX® 
T 25 basic, IKA®-Werke (Staufen, Germany) homogeneizer, to disrupt cellular structure. 
The next step was to centrifuge the samples at 13,000 g at 4ºC. The supernatant was 
collect and centrifuged again. This procedure was repeated for 2 times to make sure the 
liver’s lipids and other contaminants were properly discarded in the pellet. 
 
2.4.2 Protein Quantification 
 
The protein quantification of the lysates was assessed by the bicinchoninic acid 
assay196–198  (BCA assay).  This assay’s principle revolves around copper ion reduction 
(Cu2+ to Cu+) in an alkaline medium (figure 8). After copper was added to the protein in 
solution (in Cu2+ form), it made a blue colored compound, copper reduction occurred, 
and the Cu+ was detected by colometry via bicinchoninic acid.   
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Figure 8 Schematic representation of the BCA protocol. Adapted from Thermo Scientific 
Pierce's "Protein Assay Technical Handbook Version 2" 
 
Relative amount of protein expressed in the liver was quantified by Western Blot analysis. 
20 ug of protein was used in each Western Blot, except when using GLUT2 antibody, in 
which was used 5 µg of protein.  
 
2.4.3 SDS-PAGE 
 
 The Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) is 
a commonly used method for observing protein mass differences on an acrylamide gel. 
This method is based around the SDS compound, which when mixed with proteins in 
solution will charge every protein in sample negatively, and make them have the same 
charge density, i.e. every protein will have the same negative charge per mass. 
Afterwards, the proteins are added to a gel and “run” against an electric field, which 
makes them migrate from negative to positive pole (in the gel) and separates them by 
mass, due to the SDS properties. 
 Before performing this technique the liver had to be prepared in order to be added 
to the acrylamide gel. Samples were unfrozen and diluted in Sample Buffer (  10% β-
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mercaptoethanol, 4 % SDS, 250 mM Tris pH 7,4 , 20% glycerol , bromophenol,blue, pH 
6,8) before being denatured at 95º C for 5 minutes.  
 In order to perform the SDS-PAGE protein separation a 12 % acrylamide gel was 
prepared (0,375 M Tris pH 8,8 ; 0,2 % SDS and 0,1 % 2-Acrylamido-2-methylpropane 
sulfonic acid (AMPS)) as a “running gel” and a 4 % acrylamide gel (“stacking” gel) (0,16 
M Tris, 0,1 % SDS,  0,05 % AMPS). The selected electric current for the proteins was 
130 V, and the gel ran vertically in the appropriate buffer (125 mM Tris, 0,96 M Glycine, 
0,5% SDS, pH 8,3)  for about 1 hour and a half, or until the bromophenol blue from the 
sample buffer had left the gel. 
 
2.4.4 Electric Transfer to PVDF Membrane 
 
 Afterwards the samples were transferred from gels to polyvinylidene fluoride 
(PVDF) membranes. This transference lasted for 1 hour at 100 Volts, and was mediated 
by transference buffer (100 mM CAPS pH 11). 
 
2.4.5 Antibody blocking and detection 
 
 The membranes were then washed with distilled water and blocked in 5% milk 
with PBS before incubating the primary antibody (GLUT2, PPARα and PPARβ diluted 
in 1:1000 while Tnf-α had a 1:500 dilution, all antibodies were in 5% milk) overnight in 
cold. Afterwards the membranes were washed, blocked and then incubated at room 
temperature with secondary antibody (1:5000 anti-rabbit) 
Antibody binding was revealed with chemoluminescence, using ECF as the 
luminescent molecule. The secondary antibody had alkaline phosphatase attached to its 
terminal, this way when ECF is added luminescence can be observed in the form of a 
yellow shade on the membranes and was revealed via Versa Doc model 3000 by BioRad, 
which also allows for relative protein expression quantification. 
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2.5.4 Results analysis 
 
All results are presented in a mean plus standard error of the mean (SEM) using 
Graph Pad, version 6 (GraphPad Software, San Diego, CA, USA). When comparing two 
groups (control vs. fructose rich diet) against the hypothesis that they are different the 
Mann-Whitney-Wilcoxon test was used. Differences were considered significant when p 
< 0.05. 
  
28 
 
 
3. Results  
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3. Results  
 
3.1 Weight Gain 
 
 Mice weight was controlled throughout the study, it was measured once each two 
weeks. In figure 9 we can see how weight varied between normal chow and fructose rich 
diet fed mice for 10 weeks of dieting, it is important to note that all mice were used for 
this measurement.  
 
Figure 9 Weight control of mice from the two diet groups for 10 weeks (N=6 per group) 
 
  While overall weight gain was not significantly different between the two groups, 
the fructose fed mice had a tendency not to gain weight over the first four weeks, but then 
showed comparable rate of weight gain over the last four weeks.  This difference may 
reflect some degree of metabolic adaptation to high fructose feeding.  
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3.2 Intestinal Permeability 
 
Figure 10 Representation of the intestinal leakage of FITC-Dextran through time with 
standard error mean. The number of animals used per group were 6. 
 
 Intestinal permeability was evaluated in 3 time points in mice, after two, six and 
twelve weeks of dieting (figure 10).  Intestinal leakage values for mice fed with control 
diet were residual, in agreement to results described by Cani in 2009 59 for this intestinal 
permeability assay.  In week 2 there was already a significant difference between control 
and high fructose diets, as the experimental group had values of leakage 37,32 ± 2,149% 
, while the control group had only 0,07448 ± 0,03576% (P < 0,0001). In week 6 this 
difference was more aggravated as the high fructose fed group had leakage in the 49,96 
± 9,884% , in contrast with the control group , whose leakage also rose, and had a value 
of 2,352 ± 0,01685% (P=0,0029). By week 12 the intestinal permeability of the high 
fructose diet had decreased, (27,01 ± 3,961%) but remained significantly higher than , the 
control group had a (0,8657 ± 0,4707% , p< 0,0001).  
 Changes in permeability appear to be associated with weight changes in mice. 
For instance, in week 2 we can see a slight decrease in the weight of both groups, but a 
significant change in leakage of FITC-dextran was observed in fructose fed mice at this 
time point, as well as in week 6 when leakage reached its maximum value, which 
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corresponds to a weight increase in both groups. However a decrease in leakage can be 
observed in week 12 to the lowest values in this study, which also matches the reach of a 
weight threshold in both groups. 
  
3.3 Western Blots 
 All results for Western Blots are the result of a repletion of 4 different experiments 
with all mice (N=6) for each group (high fructose diet vs. normal chow), and were tested 
against “Mann-Whitney” statistical test and “Student t-test”. 
 
PPAR α 
 
Figure 11: Representative Western blotting (six different mice from each group) showing 
the hepatic protein content of PPARα. Densitometry analysis of specific bands from all 
mice studied is shown. Values are expressed as a percentage relative to Dextrose (100 
%) and are means versus SD. Equal loading of the gels was as demonstrated by probing 
the membranes with an anti-β-actin polyclonal antibody. P value was 0,0290 for unpaired 
t-test. Proteins bands are shown at the right of the figure. 
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Expression levels of PPAR α (Figure 11) were decreased in the liver of fructose 
rich diet fed mice when compared with the control.  The levels obtained of PPAR- α in 
the experimental group were of 79,77 ± 3,120 (P=0,029) 
 
 
PPARβ 
 
 
Figure 12:  Representative Western blotting (six different mice from each group) showing 
the hepatic protein content of PPARβ. Densitometry analysis of specific bands from all 
mice studied is shown. Values are expressed as a percentage relative to Dextrose (100 
%) and are means versus SD. Equal loading of the gels was as demonstrated by probing 
the membranes with an anti-β-actin polyclonal antibody. P value was 0,0076 for unpaired 
t-test. Proteins bands are shown at the right of the figure 
 
 Levels of PPAR-β in the liver of the test group showed small but significant 
differences from the control group, even though it has been described that it helps regulate 
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toxicity in the liver186.  The experimental group had levels of 103,9 ± 0,9966 (P=0,0076) 
of PPAR- β (figure 12). 
  
Tumor necrosis factor α (TNF-α) 
 
Figure 13: Representative Western blotting (six different mice from each group) showing 
the hepatic protein content of TNF-α. Densitometry analysis of specific bands from all 
mice studied is shown. Values are expressed as a percentage relative to Dextrose (100 
%) and are means versus SD. Equal loading of the gels was as demonstrated by probing 
the membranes with an anti-β-actin polyclonal antibody. P value was 0,0002 for unpaired 
t-test. Proteins bands are shown at the right of the figure. 
 
In figure 13 is shown that the expression of TNF- α in the liver of the test group 
has increased by nearly 30 % when compared to the control. Expression levels obtained 
for the experimental group were 127,9 ± 3,6 (P=0,0002). 
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Glucose transporter 2 (GLUT2) 
 
 
 
 
Figure 14 Representative Western blotting (six different mice from each group) showing 
the hepatic protein content of GLUT2. Densitometry analysis of specific bands from all 
mice studied is shown. Values are expressed as a percentage relative to Dextrose (100 
%) and are means versus SD. Equal loading of the gels was as demonstrated by probing 
the membranes with an anti-β-actin polyclonal antibody. P value was 0,0055 for unpaired 
t-test. Proteins bands are shown at the right of the figure 
 
 GLUT2 expression in the liver (figure 14) was increased almost two fold in the 
fructose rich diet group, with its expression levels around 180,4 ± 19,0 (P=0,0055).  
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4. Discussion  
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4. Discussion 
  
 
 The difference in intestinal permeability between high fructose diet fed mice and 
normal chow fed mice is quite substantial, and it’s clear that the experimental group had 
many times the amount of intestinal leakage that the control group at all times.  
An increase in intestinal permeability with high fructose feeding has not been 
reported yet, even though there had already been some speculation on the matter 199,200. 
The increase in permeability for the first six weeks can be assigned to the fact that fructose 
induces production of short-chain fatty acids, hydrogen and butyrate in the intestine, all 
of these metabolites were already know to be associated with luminal distension, and 
therefore could be associated with increasing intestinal leakage. The decrease in leakage 
in week 12 can probably be associated with host adaptation to the fructose rich diet, as 
the intestine’s bacteria can respond to this diet by causing small intestine overgrowth74 or 
by changing its species201. It is also implied that there could be fructose malabsorption 
related problems due to this fructose induced small intestine overgrowth72, which can lead 
to a deficiency in fructose transporters in the enterocytes30, this may as well contribute to 
a threshold in fructose absorption. Considering the impact a change in intestinal 
microbiota can have in the host61,182 , and the fact that the host can adapt its mucosal 
immunity to this change154 it is plausible for a decrease in leakage to occur in week 12.  
 The fact that intestinal leakage is increased in fructose rich diet has implications 
for the liver, as this increase means that bacterial translocation is made easier, and that 
there is an increase in the quantity of intestinal blood barrier crossing endotoxins and 
metabolites, all of these can easily reach the liver via portal vein. These pro-inflammatory 
agents, combined with the increased lipogenesis associated with high fructose ingestion, 
can lead to the development of NAFLD and NASH10. 
 A decrease in PPAR α could reflect increased transport of fatty acids and 
triglycerides from the gut into the liver.  This increase will likely induce the repressors 
for PPAR α, and down regulate anti-inflammatory proteins and factors, besides leading 
to increased synthesis of lipoproteins. A decrease in this anti-inflammatory receptor is 
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also in agreement with reports of increased inflammation (and higher production of 
cytokines) in NAFLD 157. 
 Since the production of cytokines can induce the production of mitogen activated 
kinase (MAPK), which can phosphorylate and repress PPAR-β202,203 , it is possible that 
these levels of expression of PPAR-β result from a balance of increased levels due to 
toxicity (following intestine leakage204) against increased repression of PPAR-β via 
phosphorylation. This may lead to this maintenance of PPAR-β levels in the liver, even 
though PPAR-α levels are altered. 
 The increase in Tnf-α expression concurs with the data shown in figure 11 and 12, 
as an increase in levels of this cytokine was reported for inhibiting PPAR- α expression 
in the liver205. This increase likely reflects higher intestinal leakage of endotoxin and other 
bacterially-derived pro-inflammatory agents which activate the immune system and lead 
to Tnf- α production.  This represents a mechanism that links toll like receptor activation 
and fructose induced steatosis 206.  
 The increase in GLUT2 expression is possibly due to the overproduction of 
hepatic glucose from gluconeogenic fructose metabolism.  Increased GLUT2 expression 
would mediate a more effective export of hepatic glucose into the bloodstream207. This 
result is in agreement with older research in which fructose had been associated with 
upregulation of GLUT2 mRNA in a hepatocyte cell line208. 
In table 2 the expression and possible causes and effects of the measured protein 
expressions are summarized. The increase in Tnf-α157 and the decrease in PPAR-α209 are 
in agreement with the inflammatory effects felt in NAFLD, as well as some of its 
metabolic outcomes, like the increase in lipogenesis. PPAR β had not been described yet 
in this disease.  
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 Average expression 
level ± Standard 
Deviation 
Caused by Effects 
PPAR-α 79,8 ± 3,1 Repressed by excess of fatty acids and 
TAG’s;  
Less anti-inflammatory factor 
expression ; Less lipid catabolism 
PPAR-β 103,9 ± 2,0 Increase due to liver toxicity; 
Repression by cytokines  
Higher expression of pro 
inflammatory factors: 
Tnf- α 127,0 ± 7,2 Increased by excess of fatty acids and 
of bacterial byproducts from the 
intestine; Possible macrophage 
infiltration 
Activation of inflammatory 
pathways; 
GLUT2 180,0 ± 38,0 Increased by overload of fructose Higher levels of fructose and 
glucose on the bloodstream and 
liver 
 
Table 2 Analysis of each protein expression along with the causes and effects of different 
expressions 
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5. Conclusions 
 
The effect of a high fructose diet on intestinal permeability is yet to be fully 
established, but the data on the present work are a step forward in unravelling what 
happens in this complex system. Furthermore, this also serves to show how important the 
intestine can be in forming metabolic diseases liver and how both can interact with each 
other. This also leads to the conclusion that fructose metabolism in the intestine has quite 
an impact on the mucosa itself, as leakage increased at a fast pace. The differences in the 
intestinal leakage between groups can point out to the importance that the intestine’s 
bacteria can have as therapeutic target for NAFLD and NASH, as modulation of the flora 
affects what is leaked into the portal vein and may alter the outcome of liver disease. 
Putting everything into perspective, a fructose rich diet was capable of altering the 
intestinal permeability of our mice after a short period of time (figure 10) to high levels 
of leakage. Besides giving information on how the intestine barrier is, this also points out 
to a possible increase in the production of hydrogen, carbon dioxide and short chain fatty 
acids by bacteria, after consuming fructose. This alteration will lead to a higher leakage 
of fatty acids, fructose and other metabolites into the blood stream, besides leaking toxins 
and bacterial by-products that may lead to an increased inflammatory response (figure 4). 
The hepatic portal vein delivers molecules to the liver before any other organs, therefore 
indicating that changes in the liver's metabolome and proteome are also linked to 
increased intestinal permeability. High amounts of fatty acids in the liver eventually leads 
to metabolic stress, causing PPAR alpha shutdown (figure 15). This will also contribute 
to higher TNF-alpha levels. High fructose access by the liver is indicated by the up 
regulation of GLUT2, which is overexpressed in order to regulate hepatocytes 
intracellular glucose levels and glucose homeostasis. All these changes will contribute to 
the development to NAFLD, and may even lead to NASH and cirrhosis in liver, besides 
a possibility for insulin resistance and small intestine overgrowth.  
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Concluding, there is still the need to look deeper into the intestine to figure out 
what bacteria species are associated with this increase in leakage in dietary changes, what 
is in fact the main product leaking through the intestinal blood barrier, but mostly what is 
more devastating for the host’s liver, if the bacterial translocation or the toxins and 
metabolites that are responsible for this metabolic effects. For the last, it is also quite 
important to “pin down” the mechanisms behind fructose induced enterocyte tight 
junction destruction. 
 
Figure 15 Representation of what is thought to happen in a fructose rich diet on the gut 
and the liver. 
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